poisar

Stocks · News reference

Belite Bio Submits Japanese New Drug Application For Tinlarebant In Stargardt Disease Type 1

Benzinga Newsdesk

Tinlarebant is an investigational, once-daily oral therapy for the treatment of STGD1, a rare, inherited retinal disease caused by mutations in the ABCA4 gene that leads to progressive and irreversible vision loss.

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

BLTE
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Belite Bio Announces Uplisting to the Nasdaq Global Select Market

    Belite Bio, Inc. (NASDAQ: BLTE) announced its uplisting from the Nasdaq Capital Market to the Nasdaq Global Select Market, effective October 19, 2026. The company, a clinical-stage drug developer focused on retinal diseases, achieved this milestone by meeting the higher financial and liquidity standards required. The uplisting is expected to enhance visibility among institutional investors, improve liquidity, and broaden market recognition as the company continues advancing tinlarebant, its lead candidate for Stargardt disease treatment.

    BLTE